Cargando…

Peptide VSAK maintains tissue glucose uptake and attenuates pro-inflammatory responses caused by LPS in an experimental model of the systemic inflammatory response syndrome: a PET study

The present investigation using Positron Emission Tomography shows how peptide VSAK can reduce the detrimental effects produced by lipopolysaccharides in Dutch dwarf rabbits, used to develop the Systemic Inflammatory Response Syndrome (SIRS). Animals concomitantly treated with lipopolysaccharides (L...

Descripción completa

Detalles Bibliográficos
Autores principales: Luna-Reyes, Ismael, Pérez-Hernández, Eréndira G., Delgado-Coello, Blanca, Ávila-Rodríguez, Miguel Ángel, Mas-Oliva, Jaime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292390/
https://www.ncbi.nlm.nih.gov/pubmed/34285283
http://dx.doi.org/10.1038/s41598-021-94224-2
_version_ 1783724822599041024
author Luna-Reyes, Ismael
Pérez-Hernández, Eréndira G.
Delgado-Coello, Blanca
Ávila-Rodríguez, Miguel Ángel
Mas-Oliva, Jaime
author_facet Luna-Reyes, Ismael
Pérez-Hernández, Eréndira G.
Delgado-Coello, Blanca
Ávila-Rodríguez, Miguel Ángel
Mas-Oliva, Jaime
author_sort Luna-Reyes, Ismael
collection PubMed
description The present investigation using Positron Emission Tomography shows how peptide VSAK can reduce the detrimental effects produced by lipopolysaccharides in Dutch dwarf rabbits, used to develop the Systemic Inflammatory Response Syndrome (SIRS). Animals concomitantly treated with lipopolysaccharides (LPS) and peptide VSAK show important protection in the loss of radiolabeled-glucose uptake observed in diverse organs when animals are exclusively treated with LPS. Treatment with peptide VSAK prevented the onset of changes in serum levels of glucose and insulin associated with the establishment of SIRS and the insulin resistance-like syndrome. Treatment with peptide VSAK also allowed an important attenuation in the circulating levels of pro-inflammatory molecules in LPS-treated animals. As a whole, our data suggest that peptide VSAK might be considered as a candidate in the development of new therapeutic possibilities focused on mitigating the harmful effects produced by lipopolysaccharides during the course of SIRS.
format Online
Article
Text
id pubmed-8292390
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82923902021-07-22 Peptide VSAK maintains tissue glucose uptake and attenuates pro-inflammatory responses caused by LPS in an experimental model of the systemic inflammatory response syndrome: a PET study Luna-Reyes, Ismael Pérez-Hernández, Eréndira G. Delgado-Coello, Blanca Ávila-Rodríguez, Miguel Ángel Mas-Oliva, Jaime Sci Rep Article The present investigation using Positron Emission Tomography shows how peptide VSAK can reduce the detrimental effects produced by lipopolysaccharides in Dutch dwarf rabbits, used to develop the Systemic Inflammatory Response Syndrome (SIRS). Animals concomitantly treated with lipopolysaccharides (LPS) and peptide VSAK show important protection in the loss of radiolabeled-glucose uptake observed in diverse organs when animals are exclusively treated with LPS. Treatment with peptide VSAK prevented the onset of changes in serum levels of glucose and insulin associated with the establishment of SIRS and the insulin resistance-like syndrome. Treatment with peptide VSAK also allowed an important attenuation in the circulating levels of pro-inflammatory molecules in LPS-treated animals. As a whole, our data suggest that peptide VSAK might be considered as a candidate in the development of new therapeutic possibilities focused on mitigating the harmful effects produced by lipopolysaccharides during the course of SIRS. Nature Publishing Group UK 2021-07-20 /pmc/articles/PMC8292390/ /pubmed/34285283 http://dx.doi.org/10.1038/s41598-021-94224-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Luna-Reyes, Ismael
Pérez-Hernández, Eréndira G.
Delgado-Coello, Blanca
Ávila-Rodríguez, Miguel Ángel
Mas-Oliva, Jaime
Peptide VSAK maintains tissue glucose uptake and attenuates pro-inflammatory responses caused by LPS in an experimental model of the systemic inflammatory response syndrome: a PET study
title Peptide VSAK maintains tissue glucose uptake and attenuates pro-inflammatory responses caused by LPS in an experimental model of the systemic inflammatory response syndrome: a PET study
title_full Peptide VSAK maintains tissue glucose uptake and attenuates pro-inflammatory responses caused by LPS in an experimental model of the systemic inflammatory response syndrome: a PET study
title_fullStr Peptide VSAK maintains tissue glucose uptake and attenuates pro-inflammatory responses caused by LPS in an experimental model of the systemic inflammatory response syndrome: a PET study
title_full_unstemmed Peptide VSAK maintains tissue glucose uptake and attenuates pro-inflammatory responses caused by LPS in an experimental model of the systemic inflammatory response syndrome: a PET study
title_short Peptide VSAK maintains tissue glucose uptake and attenuates pro-inflammatory responses caused by LPS in an experimental model of the systemic inflammatory response syndrome: a PET study
title_sort peptide vsak maintains tissue glucose uptake and attenuates pro-inflammatory responses caused by lps in an experimental model of the systemic inflammatory response syndrome: a pet study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292390/
https://www.ncbi.nlm.nih.gov/pubmed/34285283
http://dx.doi.org/10.1038/s41598-021-94224-2
work_keys_str_mv AT lunareyesismael peptidevsakmaintainstissueglucoseuptakeandattenuatesproinflammatoryresponsescausedbylpsinanexperimentalmodelofthesystemicinflammatoryresponsesyndromeapetstudy
AT perezhernandezerendirag peptidevsakmaintainstissueglucoseuptakeandattenuatesproinflammatoryresponsescausedbylpsinanexperimentalmodelofthesystemicinflammatoryresponsesyndromeapetstudy
AT delgadocoelloblanca peptidevsakmaintainstissueglucoseuptakeandattenuatesproinflammatoryresponsescausedbylpsinanexperimentalmodelofthesystemicinflammatoryresponsesyndromeapetstudy
AT avilarodriguezmiguelangel peptidevsakmaintainstissueglucoseuptakeandattenuatesproinflammatoryresponsescausedbylpsinanexperimentalmodelofthesystemicinflammatoryresponsesyndromeapetstudy
AT masolivajaime peptidevsakmaintainstissueglucoseuptakeandattenuatesproinflammatoryresponsescausedbylpsinanexperimentalmodelofthesystemicinflammatoryresponsesyndromeapetstudy